essence study semaglutide A New Phase in MASH Therapeutics: Resmetirom (THR-β Agonist) and (GLP-1 Receptor Agonist) Phase 3 Trial of Semaglutide

& Peskov, K

7 Systemic metabolic disorders that contribute to Alzheimer's disease 7.1 Diabetes, insulin resistance and metabolic syndrome The complex interplay of diabetes, dyslipidemia, obesity, and hypertension in clinical settings makes it challenging to pinpoint their individual roles in pathology

As a result of the trial's findings, Novo Nordisk said it plans to file for a "label indication expansion" for the drug, meaning it could be available beyond obesity, and with greater insurance coverage

We work with you to ensure the medication is administered safely and that youre monitored for any side effects, keeping your health and safety our top priority

For a deeper look at the science, see our guide to All About Liposomes